Dr. Blain is an internationally known expert in cell cycle and cancer biology, and has been studying cell cycle regulation almost 30 years. She is the co-founder of CONCARLO Therapeutics, which has the goal of developing diagnostic and therapeutic applications for drug resistant cancers, by drugging the novel target p27Kip1. CONCARLO’s therapeutic, IpY, will be used to treat drug-resistant, ER/PR+, Her2- metastatic breast cancer patients. CONCARLO’s ApY, is a companion diagnostic to identify patients non-responsive to cdk4 inhibitory therapies and responsive to IpY. CONCARLO has been awarded highly competitive SBIR funding from the NIH and a contract with the NIH Nanoparticle Characterization Lab. Dr. Blain is also an NIH funded investigator and Associate Professor in Cell Biology and Pediatrics at the SUNY Downstate Medical Center, who has several basic science and translational projects, studying the role of the oncogene cyclin D-cdk4 and p27 in breast cancer. Her lab is currently funded by the NIH and the METAvivor Foundation. Dr. Blain is an internationally known expert in cell cycle and cancer biology, and has been studying cell cycle regulation almost 30 years. She is the co-founder of CONCARLO Therapeutics, which has the goal of developing diagnostic and therapeutic applications for drug resistant cancers, by drugging the novel target p27Kip1. CONCARLO’s therapeutic, IpY, will be used to treat drug-resistant, ER/PR+, Her2- metastatic breast cancer patients. CONCARLO’s ApY, is a companion diagnostic to identify patients non-responsive to cdk4 inhibitory therapies and responsive to IpY. CONCARLO has been awarded highly competitive SBIR funding from the NIH and a contract with the NIH Nanoparticle Characterization Lab. Dr. Blain is also an NIH funded investigator and Associate Professor in Cell Biology and Pediatrics at the SUNY Downstate Medical Center, who has several basic science and translational projects, studying the role of the oncogene cyclin D-cdk4 and p27 in breast cancer. Her lab is currently funded by the NIH and the METAvivor Foundation.

• 

  Founder, CEO in Concarlo Therapeutics

  Developing solutions for drug-resistant cancer